Providing Contraception for Young People During a Pandemic Is Essential Health Care

Trae Wilkinson, MD, MPH
Department of Pediatrics/Children's Health Services Research, Indiana University School of Medicine, Indianapolis.

Melissa J. Kottke, MD, MPH
Jane Fonda Center, Department of Gynecology and Obstetrics, Emory University School of Medicine, Atlanta, Georgia.

Elise D. Berlan, MD, MPH
Division of Adolescent Medicine, Department of Pediatrics, The Ohio State University College of Medicine, Columbus.

Adolescent and young adult reproductive health care needs are not diminished during pandemics. Needs for family planning services may be heightened because of various environmental changes in response to the pandemic, including amount of parental supervision, daily structure, and usual ways of accessing contraception and condoms. Health care professionals (HCPs) caring for adolescent and young adult patients need to acknowledge that contraception is an essential need and adopt new approaches to providing this crucial care.

In response to the coronavirus disease 2019 (COVID-19) pandemic, HCPs are exploring ways to ensure delivery of essential health care services and minimize exposure risks to personnel and patients, including virtual care. Fortunately, both telephone and video platforms are well suited to providing contraceptive care. While an in-person encounter may be ideal, many reproductive health care services can be performed virtually, including contraception counseling, provision and maintenance of regular and emergency contraception, and sexual risk-reduction counseling. We propose the following approach for providing contraception to adolescents during COVID-19 that leverages virtual care and minimizes the need for in-person visits (Figure). This approach can be used by many HCPs and across telehealth and in-person settings.

Safe provision of contraception relies largely on history and rarely requires a physical examination, pelvic or breast examinations, sexually transmitted infection, or cervical cancer screenings. Much of the information needed can be obtained from the patient history, including patient-reported or previously recorded blood pressure. The US Medical Eligibility Criteria for Contraceptive Use provides guidance on contraindications to contraceptives based on the patient history and is available in many forms, including a smartphone application.

A challenge in conducting telehealth with adolescents is patient privacy; adolescents may not have a private space and HCPs may not be able to reliably assess whether an adolescent’s verbal communication is actually private. It is important to explore who is in the room and if the patient can speak freely. We recommend using clinical judgement to guide whether you can safely ask about sensitive content and how much you need to obtain. It is not necessary to obtain a complete sexual history to prescribe contraceptives. Consider using yes/no questions for sensitive topics, such as interest in contraception, sexual history, and pregnancy screening.

Fortunately, a healthy young person with no active or previous medical conditions who takes no medications or supplements can safely use any reversible contraceptive method. Using contraception is very safe and is safer than pregnancy. HCPs can ask questions to be reasonably certain a person is not pregnant. If there are no signs or symptoms of pregnancy and the patient meets additional criteria as identified in the US Medical Eligibility Criteria for Contraceptive Use (Figure), contraception, other than intrauterine contraception, can be administered immediately. Even in situations in which an HCP is not reasonably certain a person is not pregnant, the benefits of administering contraception that day (except intrauterine devices) generally outweigh the risks, as none of the contraceptive methods are known to be teratogenic or abortifacient.

Health care professionals can encourage patients to take a home pregnancy test in these situations.

Contraception counseling can be performed virtually using shared decision-making to incorporate patients’ preferences and priorities. Clinicians may consider incorporating high-quality resources, including videos and images, such as those available at bedsider.org, before, during (screen-sharing), or after their virtual patient encounter. Pills, transdermal patch, and vaginal rings can be refilled or initiated on the day of the telehealth encounter and a 12-month supply should be provided. After initiation, use of a backup method for 7 days is recommended. Progestin-only contraceptive pills (norethindrone and drospirenone) are an option for those with a medical contraindication to estrogen.

Depot medroxyprogesterone acetate is a progestin-only method available as a 150-mg intramuscular or 104-mg subcutaneous injection. Traditionally, it is administered every 3 months in a clinical setting. However, during pandemic times, HCPs can consider extending the dosing interval to 15 weeks and exploring creative approaches to intramuscular delivery (eg, curbside). Alternatively, the subcutaneous form may be prescribed along with alcohol swabs for self-administration at home. Medication teaching can be provided verbally, by video, and/or via a patient information sheet, such as the one made by the Reproductive Health Access Project.

For the patient who is interested in a long-acting reversible contraceptive method (ie, an intrauterine device or implant), a shorter-acting contraceptive should be offered to provide contraception while awaiting in-person placement. People currently using a long-acting reversible contraceptive method near the end of their US Food and Drug Administration–approved length of use can be reassured that these devices have contraceptive benefit beyond the approved window.

Counseling patients about using emergency contraception pills (ie, levonorgestrel, 1.5 mg, and ulipristal acetate, 30 mg) and offering an advanced prescription may be particularly beneficial now to reduce patient cost and access barriers. Ulipristal acetate is more effective than levonorgestrel, particularly for those who have a
Figure. Algorithm for Providing Contraception for Young People During a Pandemic

**Patient contact**
- Review medical record and last BP measurement

**Ensure privacy**
- Are you somewhere that you can talk privately?
  - Yes
  - No
  - Patient-centered contraceptive counseling with shared decision-making

**Are you interested in talking about pregnancy prevention today?**
- Yes
- No

**Are you currently using any method of contraception?**
- Yes
- No

**Are you satisfied with this method?**
- Yes
- No

**Short-acting method (pill/patch/ring)**
- Prescribe method with 12-mo supply

**Long-acting contraceptive (LARC)**
- LARC extended use
- Subcutaneous route prescribed and self-administered
- Clinic visit with short-acting method
- Prescribe bridge to clinic visit with short-acting method
- Contraindications are not excluded
- Prescribe progestin-only after (norethindrone or drospirenone)

**Pregnancy exclusion questions**
- All methods can be started immediately if HCP is reasonably certain person is not pregnant if patient has no signs or symptoms of pregnancy and answers yes to any of the following questions:
  1. Did your period start in the last 7 days?
  2. Have you been using a reliable birth control method consistently and correctly?
  3. Have you not had sex since your last period?
  4. Have you had a baby in the last 4 wk or a miscarriage/abortion in the last 7 days?
  5. Are you exclusively breastfeeding a baby <6 mo old and your periods haven’t returned?
- If a person answers no to each of these and it has been >4 wk since LMP, consider a pregnancy test. In these situations, the benefits of starting contraception (except for IUD) outweigh the risks. Condoms should be used for backup and dual protection, and a pregnancy test 2 and 4 wk after initiation should be performed.

**Review medical contraindication questions**
- Have you recently given birth or are currently breastfeeding?
- Have you ever been told you have high blood pressure?
- Have you ever been told you have diabetes and have complications from it?
- Have you ever had a stroke, blood clot in your legs or lungs, or heart attack, or been told you are prone to having blood clots?
- Do you have a history of migraines with aura (headaches that started with warning signs or symptoms, such as flashes of light, blind spots, or tingling in your hands or face that come before the headache starts)?
- Do you regularly take pills for seizures, tuberculosis, or HIV?
- Do you have gallbladder disease or serious liver disease, or jaundice?
- Have you ever been told you have rheumatic disease, such as lupus?
- Have you ever been told you have breast cancer or an undiagnosed breast lump?

**Are you somewhere that you can talk privately?**
- Yes
- No

**Are you interested in talking about pregnancy prevention today?**
- Yes
- No

**Are you currently using any method of contraception?**
- Yes
- No

**Are you satisfied with this method?**
- Yes
- No

**Short-acting method (pill/patch/ring)**
- Prescribe method with 12-mo supply

**Long-acting contraceptive (LARC)**
- LARC extended use
- Subcutaneous route prescribed and self-administered
- Clinic visit with short-acting method
- Prescribe bridge to clinic visit with short-acting method
- Contraindications are not excluded
- Prescribe progestin-only after (norethindrone or drospirenone)

AYA indicates adolescents and young adults; BP, blood pressure; DMPA, depot medroxyprogesterone acetate; EC, emergency contraception; HCP, health care professional; IUD, intrauterine contraceptive device; LARC, long-acting reversible contraception; US MEC, US medical eligibility criteria for contraceptive use.

body mass index (calculated as weight in kilograms divided by height in meters squared) above 30 or who had sex more than 72 hours ago. Patients who take ulipristal acetate for emergency contraception should wait 5 days to take a hormonal contraceptive and use condoms until their next menses. It is also important to encourage consistent condom use for sexually transmitted infection prevention, backup for birth control, and dual protection. For any contraceptive method prescribed, clinicians should review the options for obtaining the product (eg, purchasing or filling a prescription at a pharmacy and online/telephone ordering with home delivery). After a method is chosen, HCPs should inform patients to contact them if there are costs or insurance barriers during the pandemic.

In addition to these approaches, 11 states and the District of Columbia allow for pharmacist-prescribed contraception. Further, some private companies provide telehealth options for home delivery of contraceptives. However, we believe it is possible and imperative for HCPs to prioritize contraception access for young people throughout this pandemic and beyond as essential health care.

**ARTICLE INFORMATION**


Conflict of Interest Disclosures: Dr Berlan is a consultant to Merck and Bayer and is a Nexplanon clinical trial. No other disclosures were reported.

REFERENCES


